SecBot SecBot
PRESS-RELEASE ·Filed Apr 29, 2026

EBS

Emergent BioSolutions
BULLISH
Impact 4/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ▲ Bullish

The contract adds a new revenue stream, but the contingent portion depends on SAB-142's clinical and regulatory success. Monitor SAB-142 trial updates and milestone announcements for revenue recognition triggers.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.99
T+0 close · Apr 29, 2026 · via day close
Latest settled
−9.14%
T+60 · $7.26
Vs SPY
−13.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 29 $7.99entry
  2. T+1 · 7mo ago +3.00%α +1.98% · $8.23
  3. T+5 · 7mo ago +13.89%α +10.78% · $9.10
  4. T+20 · 6mo ago +14.89%α +8.85% · $9.18
  5. T+60 · 4mo ago −9.14%α −13.25% · $7.26

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Emergent BioSolutions announced a multi-year agreement with SAB Biotherapeutics to provide manufacturing services for SAB-142, a clinical-stage treatment for type 1 diabetes. The deal is valued at approximately $50 million, with $36 million contingent on regulatory milestones, providing moderate revenue upside for EBS.

Key Financial Metrics

Deal Value
$50.0M

Key Facts

  • Emergent BioSolutions signs multi-year manufacturing agreement with SAB Biotherapeutics
  • Agreement valued at ~$50 million, with $36 million contingent on regulatory approval and milestones
  • Services include process development, scale-up, and manufacturing for SAB-142, a T1D treatment
  • Manufacturing to take place at Emergent's Winnipeg facility

Financial Impact

Approximately $14 million in near-term revenue (guaranteed portion) with potential total of $50 million if all milestones met

revenue

Risk Factors

  • Only $14M is guaranteed; $36M contingent on regulatory approval and milestones
  • SAB-142 is in clinical development; risk of trial failure or regulatory delay
  • Manufacturing contracts may have lower margins than proprietary products

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3283664

Track record

23 reports on EBS

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +14.87% at T+60 after the Apr 16, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $5.76 Now $5.81 +0.96% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.75 Now $5.81 +1.13% settles Nov 23
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.79 Now $5.81 +0.35% settles Nov 23
  4. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $5.85 to $5.89 Now $5.81 −0.68% ▲ +0.68% −2.61% vs SPY
  5. Nov 2, 202614d ago 8-K Bearish 6/10 Entry $6.25 to $6.05 Now $5.81 +7.04% ▲ +3.20% +2.61% vs SPY
  6. Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $6.81 to $6.06 Now $5.81 −14.68% ▼ −11.01% −8.31% vs SPY
  7. Oct 16, 20264w ago 8-K Neutral 3/10 Entry $6.38 to $6.23 Now $5.81 −8.93% ▼ −2.35% −2.44% vs SPY
  8. Oct 7, 20265w ago 144 Neutral 2/10 Entry $6.81 to $7.18 Now $5.81 −14.68% ▲ +5.43% +5.71% vs SPY
  9. Jun 29, 202620w ago 8-K Bullish 5/10 Entry $8.46 to $8.18 Now $5.81 −31.32% ▼ −3.31% −4.70% vs SPY
  10. Jun 4, 202623w ago Press Release Neutral 2/10 Entry $8.44 to $8.39 Now $5.81 −31.16% ▼ −0.59% +1.96% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 29, 2026